Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.71 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.51 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754419 | 0.89 | CTSB (0.71) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2601897 | 0.89 | CTSB (0.71) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17754421 | 0.89 | CTSB (0.71) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22192866 | 0.86 | CTSB (0.76) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2601893 | 0.86 | CTSB (0.70) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17754427 | 0.86 | CTSB (0.76) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18944133 | 0.86 | CTSB (0.70) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6447570 | 0.85 | CTSB (0.66) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6447573 | 0.85 | CTSB (0.66) | CTSBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17754418 | 0.83 | CTSB (1.00) | CTSBPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163953-B2 | Compounds for lysosomal modulation and methods of use | UNIVERSITY OF CONNECTICUT (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163953-B2 | Compounds for lysosomal modulation and methods of use | UNIVERSITY OF CONNECTICUT (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090281178-A1 | Compounds for Lysosomal Modulation and Methods of Use | UNIVERSITY OF CONNECTICUT | 2009-11-12 | — | — | US | disclosed |
| US-20090281178-A1 | Compounds for Lysosomal Modulation and Methods of Use | UNIVERSITY OF CONNECTICUT | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281178-A1 | Compounds for Lysosomal Modulation and Methods of Use | GAA, GBA1, CTSA | CTSB 14/4885PSEN1 54/4885PSEN2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.